Cargando…
The evolving role of alemtuzumab (Campath-1H) in renal transplantation
The introduction of new immunosuppressive agents into clinical transplantation in the 1990s has resulted in excellent short-term graft survival. Nonetheless, extended long-term graft outcomes have not been achieved due in part to the nephrotoxic effects of calcineurin inhibitors (CNIs) and the adver...
Autores principales: | Pham, Phuong-Thu T, Lipshutz, Gerald S, Pham, Phuong-Truc T, Kawahji, Joseph, Singer, Jennifer S, Pham, Phuong-Chi T |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769238/ https://www.ncbi.nlm.nih.gov/pubmed/19920920 |
Ejemplares similares
-
Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis
por: Dalakas, Marinos C., et al.
Publicado: (2009) -
Hypomagnesemia: a clinical perspective
por: Pham, Phuong-Chi T, et al.
Publicado: (2014) -
New onset diabetes after transplantation (NODAT): an overview
por: Pham, Phuong-Thu T, et al.
Publicado: (2011) -
Optimal use of SGLT2 inhibitors in diabetic kidney transplant recipients
por: Pham, Phuong-Thu T., et al.
Publicado: (2022) -
Conivaptan: a step forward in the treatment of hyponatremia?
por: Hline, Su Su, et al.
Publicado: (2008)